About Knight Therapeutics, Inc. 
Knight Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Knight Therapeutics Inc is a Canada-based specialty pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices. The Company’s products are ILUVIEN Fluocinolone acentonid, Nerlynx Neratinib Tablets, Burinex Bumetanide, Probuphine Buprenorphine implant and Movantik Naloxegol.
Company Coordinates 
Company Details
3400 De Maisonneuve Blvd W , MONTREAL QC : H3Z 3B8
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.15%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Mr. James Gale
Independent Chairman of the Board
Ms. Samira Sakhia
President, Director
Mr. Jonathan Goodman
Chief Executive Officer, Director
Mr. Robert Lande
Independent Director
Ms. Janice Murray
Independent Director
Mr. Nicolas Sujoy
Independent Director
Mr. Michael Tremblay
Independent Director
Revenue and Profits:
Net Sales:
107 Million
(Quarterly Results - Jun 2025)
Net Profit:
-13 Million
Pharmaceuticals & Biotechnology
CAD 581 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.01
-0.11%
0.76






